2,4-Dimethyl-5-propylthiazole | 41981-70-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2,4-Dimethyl-5-propylthiazole
• 英文别名: 2,4-dimethyl-5-propyl-1,3-thiazole
• CAS: 41981-70-8
• 化学式: C₈H₁₃NS
• mdl: MFCD18451321
• 分子量: 155.26
• InChiKey: BNONKJGVAXAEFW-UHFFFAOYSA-N

物化性质

• 保留指数：
  1157;1157

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Substituted hydroxamic acids and uses thereof
  申请人：Blackburn Christopher

  公开号：US20110046157A1

  公开（公告）日：2011-02-24

  This invention provides compounds of formula (I): wherein R 1 , R 2 , G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  本发明提供了式(I)的化合物： 其中R1、R2、G、n、p和q的值如说明书所述，可用作HDAC6的抑制剂。该发明还提供了包括该发明中的化合物的制药组合物以及使用该组合物治疗增生性、炎症性、感染性、神经系统或心血管疾病或紊乱的方法。
• P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN
  申请人：Burgey Christopher S

  公开号：US20100266714A1

  公开（公告）日：2010-10-21

  The subject invention relates to novel P2X 3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X 3 receptor subunit modulator.

  本发明涉及一种新型的P2X3受体拮抗剂，它在治疗与疼痛有关的疾病状态中发挥关键作用，特别是可以使用P2X3受体亚单位调节剂治疗的外周疼痛、炎性疼痛或组织损伤疼痛。
• MIXTURES OF MESOIONIC PESTICIDES
  申请人：Holyoke, JR. Caleb William

  公开号：US20120115722A1

  公开（公告）日：2012-05-10

  Disclosed are compositions comprising (a) at least one compound selected from compounds of Formula 1, N-oxides, and salt thereof, wherein R 1 is phenyl optionally substituted with up to 5 substituents independently selected from R 3 , or pyridinyl optionally substituted with up to 4 substituents independently selected from R 3 ; R 2 is C 1 -C 4 haloalkyl; or thiazolyl, pyridinyl or pyrimidinyl, each optionally substituted with up to 2 substituents independently selected from the group consisting of halogen and C 1 -C 4 alkyl; each R 3 is independently halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C(R 4 )═NOR 4 or Q; each R 4 is independently C 1 -C 4 alkyl; Z is CH═CH or S; and each Q is independently phenyl or pyridinyl, each optionally substituted with up to 3 substituents independently selected from the group consisting of halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy and C 1 -C 4 haloalkoxy; and (b) at least one invertebrate pest control agent. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a composition of the invention.

  本发明涉及一种组合物，包括（a）至少一种选择自式1化合物，N-氧化物和其盐的化合物，其中R1是苯基，可选地取代最多5个独立选择自R3的取代基，或者是吡啶基，可选地取代最多4个独立选择自R3的取代基；R2是C1-C4卤代烷基；或噻唑基，吡啶基或嘧啶基，每个基可选地取代最多2个独立选择自卤素和C1-C4烷基的基团；每个R3是独立的卤素，氰基，C1-C4烷基，C1-C4卤代烷基，C1-C4烷氧基，C1-C4卤代烷氧基，C（R4）═NOR4或Q；每个R4是独立的C1-C4烷基；Z是CH═CH或S；每个Q是独立的苯基或吡啶基，可选地取代最多3个独立选择自卤素，氰基，C1-C4烷基，C1-C4卤代烷基，C1-C4烷氧基和C1-C4卤代烷氧基的基团；和（b）至少一种无脊椎动物害虫控制剂。本发明还涉及一种控制无脊椎动物害虫的方法，包括用本发明组合物的生物有效量接触无脊椎动物害虫或其环境。
• PHARMACEUTICAL COMPOSITION COMPRISING GLUTARIMIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF EOSINOPHILIC DISEASES
  申请人：Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises"

  公开号：EP3466425A1

  公开（公告）日：2019-04-10

  The present invention relates to novel biologically active glutarimide derivatives of general formula (I) or a pharmaceutically acceptable salt thereof, their use as a therapeutic agent for the treatment of eosinophilic diseases, preferably of allergic nature, in particular bronchial asthma, allergic rhinitis, polypous rhinosinusopathies, eosinophilic colitis, eosinophilic syndrome, allergic conjunctivitis, atopic dermatitis, Churg-Strauss syndrome, anaphylactic shock, Quincke's edema, eosinophilic vasculitis, eosinophylic esophagitis, eosinophilic gastroenteritis, or fibroses. The invention also relates to pharmaceutical compositions comprising glutarimide derivatives of general formula (I):

  本发明涉及通式(I)的新型生物活性戊二酰亚胺衍生物或其药学上可接受的盐，以及它们作为治疗剂用于治疗嗜酸性粒细胞疾病，最好是过敏性疾病，特别是支气管哮喘、过敏性鼻炎、多发性鼻窦炎、嗜酸性粒细胞结肠炎、嗜酸性粒细胞综合征、过敏性结膜炎、特应性皮炎、Churg-Strauss 综合征、过敏性休克、Quincke 水肿、嗜酸性粒细胞血管炎、嗜酸性粒细胞食管炎、嗜酸性粒细胞胃肠炎或纤维瘤。本发明还涉及包含通式（I）戊二酰亚胺衍生物的药物组合物：
• IMIDAZOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
  申请人：Bristol-Myers Squibb Company

  公开号：EP2892899B1

  公开（公告）日：2018-03-21

表征谱图